HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

Prospective identification of tumorigenic breast cancer cells

Al‐Hajj, M., Wicha, M. S., Benito‐Hernández, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,388 · see citing works

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735 · see citing works

Comprehensive molecular profiling of lung adenocarcinoma

The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732 · see citing works

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · see citing works

A human colon cancer cell capable of initiating tumour growth in immunodeficient mice

O'Brien, C. A., Pollett, A. F., Gallinger, S., & Dick, J. E. (2006) · Nature · doi:10.1038/nature05372 · Cited by 4,089 · see citing works

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381 · see citing works

First-Line Crizotinib versus Chemotherapy in <i>ALK</i> -Positive Lung Cancer

Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190 · see citing works

Prospective Identification of Tumorigenic Prostate Cancer Stem Cells

Collins, A. T., Berry, P. A., Hyde, C. F., Stower, M. J., & Maitland, N. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2018 · Cited by 2,821 · see citing works

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

Abou‐Alfa, G. K., Meyer, T., Cheng, A., El-Khoueiry, A. B., Rimassa, L., Ryoo, B., Çiçin, İ., Merle, P., Chen, Y.-H., Park, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1717002 · Cited by 2,347 · see citing works

Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product

Bottaro, D. P., Rubin, J. S., Faletto, D. L., Chan, A. M.-L., Kmiecik, T. E., Woude, G. F. V., & Aaronson, S. A. (1991) · Science · doi:10.1126/science.1846706 · Cited by 2,242 · see citing works

Crypt stem cells as the cells-of-origin of intestinal cancer

Barker, N., Ridgway, R. A., van Es, J. H., van de Wetering, M., Begthel, H., van den Born, M., Danenberg, E., Clarke, A. R., Sansom, O. J., & Clevers, H. C. (2008) · Nature · doi:10.1038/nature07602 · Cited by 2,159 · see citing works

Molecular cloning and expression of human hepatocyte growth factor

Nakamura, T., Nishizawa, T., Hagiya, M., Seki, T., Shimonishi, M., Sugimura, A., Tashiro, K., & Shimizu, S. (1989) · Nature · doi:10.1038/342440a0 · Cited by 2,158 · see citing works

Wnt activity defines colon cancer stem cells and is regulated by the microenvironment

Vermeulen, L., De Sousa E Melo, F., van der Heijden, M., Cameron, K., de Jong, J. H., Borovski, T., Tuynman, J. B., Todaro, M., Merz, C., Rodermond, H., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2048 · Cited by 1,804 · see citing works

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771 · see citing works

<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib

Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598 · see citing works

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

Schmidt, L. S., Duh, F.-M. C., Chen, F., Kishida, T., Glenn, G. M., Choyke, P. L., Scherer, S. W., Zhuang, Z., Lubensky, I. A., Dean, M. C., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,517 · see citing works

Metabolic pathways promoting cancer cell survival and growth

Boroughs, L. K., & DeBerardinis, R. J. (2015) · Nature Cell Biology · doi:10.1038/ncb3124 · Cited by 1,459 · see citing works

Scatter factor is a fibroblast-derived modulator of epithelial cell mobility

Stoker, M. G. P., Gherardi, E., Perryman, M., & Gray, J. (1987) · Nature · doi:10.1038/327239a0 · Cited by 1,316 · see citing works

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311 · see citing works

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Choueiri, T. K., Escudier, B. J., Powles, T. B., Mainwaring, P. N., Rini, B. I., Donskov, F. N., Hammers, H. J., Hutson, T. E., Lee, J., Peltola, K. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510016 · Cited by 1,245 · see citing works

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30098-5 · Cited by 1,244 · see citing works

Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats

Nakamura, T., Nawa, K., & Ichihara, A. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91253-1 · Cited by 1,134 · see citing works

Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy

Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019 · see citing works

Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer

Wolf, J., Seto, T., Han, J., Reguart, N., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Hida, T., de Jonge, M. J. A., Orlov, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002787 · Cited by 1,004 · see citing works

Molecular cloning of a new transforming gene from a chemically transformed human cell line

Cooper, C. S., Park, M., Blair, D. G., Tainsky, M. A., Huebner, K., Croce, C. M., & Woude, G. F. V. (1984) · Nature · doi:10.1038/311029a0 · Cited by 991 · see citing works

The landscape of kinase fusions in cancer

Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C. (2014) · Nature Communications · doi:10.1038/ncomms5846 · Cited by 968 · see citing works

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Choueiri, T. K., Escudier, B. J., Powles, T. B., Tannir, N. M., Mainwaring, P. N., Rini, B. I., Hammers, H. J., Donskov, F. N., Roth, B. J., Peltola, K. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30107-3 · Cited by 964 · see citing works

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

Cui, J. J., Tran‐Dubé, M., Shen, H., Nambu, M. D., Kung, P., Pairish, M., Jia, L., Meng, J. J., Funk, L. A., Botrous, I., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2007613 · Cited by 953 · see citing works

Cancer metastases: challenges and opportunities

Guan, X. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.07.005 · Cited by 946 · see citing works

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

Paik, P. K., Felip, E., Veillon, R., Sakai, H., Cortot, A. B., Garassino, M. C., Mazières, J., Viteri, S., Senellart, H., van Meerbeeck, J. P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004407 · Cited by 887 · see citing works

Cancer Stem Cells: Basic Concepts and Therapeutic Implications

Nassar, D., & Blanpain, C. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044438 · Cited by 869 · see citing works

Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

Frampton, G. M., Ali, S. M., Rosenzweig, M., Chmielecki, J., Lu, X., Bauer, T. M., Akimov, M., Bufill, J. A., Lee, C., Jentz, D., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0285 · Cited by 796 · see citing works

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

Westover, D., Zugazagoitia, J., Cho, B. C., Lovly, C. M., & Paz-Ares, L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx703 · Cited by 766 · see citing works

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

Choueiri, T. K., Halabi, S., Sanford, B. L., Hahn, O. M., Michaelson, M. D., Walsh, M. K., Feldman, D. R., Olencki, T. E., Picus, J., Small, E. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7398 · Cited by 723 · see citing works

MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

Awad, M. M., Oxnard, G. R., Jackman, D. M., Savukoski, D. O., Hall, D., Shivdasani, P., Heng, J. C., Dahlberg, S. E., Janne, P. A., Verma, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4600 · Cited by 697 · see citing works

Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells.

Weidner, K. M., Behrens, J., Vandekerckhove, J. S., & Birchmeier, W. (1990) · The Journal of Cell Biology · doi:10.1083/jcb.111.5.2097 · Cited by 684 · see citing works

Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies

Harding, J. J., Nandakumar, S., Armenia, J., Khalil, D. N., Albano, M., Ly, M., Shia, J., Hechtman, J. F., Kundra, R., El Dika, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2293 · Cited by 602 · see citing works

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

Hugo, W., Shi, H., Sun, L., Piva, M., Song, C., Kong, X., Moriceau, G., Hong, A., Dahlman, K. B., Johnson, D. B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.061 · Cited by 596 · see citing works

Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non–Small Cell Lung Cancer

Ma, P. C., Jagadeeswaran, R., Jagadeesh, S., Tretiakova, M., Nallasura, V., Fox, E. A., Hansen, M., SCHAEFER, E. M., Naoki, K., Lader, A. S., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2650 · Cited by 576 · see citing works

Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors.

Park, M., Dean, M. C., Kaul, K. L., Braun, M. J., Gonda, M. A., & Woude, G. V. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.18.6379 · Cited by 554 · see citing works

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

Kurzrock, R., Sherman, S. I., Ball, D. W., Forastiere, A. A., Cohen, R. B., Mehra, R., Pfister, D. G., Cohen, E. E. W., Janisch, L., Nauling, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4145 · Cited by 550 · see citing works

Targeting Cancer Stemness in the Clinic: From Hype to Hope

Saygin, C., Matei, D., Majeti, R., Reizes, O., & Lathia, J. D. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2018.11.017 · Cited by 517 · see citing works

A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor.

Rubin, J. S., Chan, A. M.-L., Bottaro, D. P., Burgess, W. H., Taylor, W., Cech, A. C., Hirschfield, D. W., Wong, J., Miki, T., & Finch, P. W. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.2.415 · Cited by 493 · see citing works

Somatic Mutations Lead to an Oncogenic Deletion of Met in Lung Cancer

Kong-Beltran, M., Seshagiri, S., Zha, J., Zhu, W., Bhawe, K. M., Mendoza, N., Holcomb, T., Pujara, K., Stinson, J., Fu, L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2749 · Cited by 491 · see citing works

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

Smolen, G. A., Sordella, R., Muir, B., Mohapatra, G., Barmettler, A., Archibald, H., Kim, W. J., Okimoto, R. A., Bell, D. W., Sgroi, D. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508776103 · Cited by 484 · see citing works

Mutation of the c-Cbl TKB Domain Binding Site on the Met Receptor Tyrosine Kinase Converts It into a Transforming Protein

Peschard, P., Fournier, T. M., Lamorte, L., Naujokas, M. A., Band, H., Langdon, W. Y., & Park, M. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00378-1 · Cited by 462 · see citing works

Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer.

Renzo, M. F. D., Olivero, M., Giacomini, A., Porte, H., Chastre, E., Mirossay, L., Nordlinger, B., Bretti, S., Bottardi, S., & Giordano, S. (1995) · PubMed · Cited by 456 · see citing works

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.

Ma, P. C., Kijima, T., Maulik, G., Fox, E. A., Sattler, M., Griffin, J. D., Johnson, B. E., & Salgia, R. (2003) · PubMed · Cited by 454 · see citing works

Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytes.

Zarnegar, R., & Michalopoulos, G. K. (1989) · PubMed · Cited by 448 · see citing works

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

Smith, D. C., Smith, M. R., Sweeney, C. J., Elfiky, A. A., Logothetis, C. J., Corn, P. G., Vogelzang, N. J., Small, E. J., Harzstark, A. L., Gordon, M. S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.0494 · Cited by 446 · see citing works

Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification

Ou, S. I., Kwak, E. L., Siwak, C. T., Dy, J., Bergethon, K. E., Clark, J. W., Camidge, D. R., Solomon, B., Maki, R. G., Bang, Y., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31821528d3 · Cited by 435 · see citing works

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer

Solomon, B., Kim, D., Wu, Y.-L. L. C., Nakagawa, K., Mekhail, T. M., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., Tang, Y., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.4794 · Cited by 408 · see citing works

RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomasPreprint

Bao, Z., Chen, H.-M., Yang, M.-Y., Zhang, C., Yu, K., Ye, W.-L., Hu, B.-Q., Yan, W., Zhang, W., Akers, J. C., et al. (2014) · Genome Research · doi:10.1101/gr.165126.113 · Cited by 404 · see citing works

Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

Zhou, L., Liu, X.-D., Sun, M., Zhang, X., German, P., Bai, S., Ding, Z., Tannir, N. M., Wood, C. G., Matin, S. F., et al. (2015) · Oncogene · doi:10.1038/onc.2015.343 · Cited by 400 · see citing works

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

Drilon, A. E. D. C., Clark, J. W., Weiss, J. M., Ou, S. I., Camidge, D. R., Solomon, B., Otterson, G. A., Villaruz, L. C., Riely, G. J., Heist, R. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0716-8 · Cited by 396 · see citing works

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Hanna, N. H. (2008) · Yearbook of Oncology · doi:10.1016/s1040-1741(08)79219-4 · Cited by 386 · see citing works

Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer

Bacco, F. D., Luraghi, P., Médico, E., Reato, G., Girolami, F., Perera, T. P. S., Gabriele, P., Comoglio, P. M., & Boccaccio, C. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr093 · Cited by 364 · see citing works

10.1016/j.ypdi.2015.02.054

(2000) · Time to knit · doi:10.1016/j.ypdi.2015.02.054 · Cited by 353 · see citing works

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations

Liu, X., Jia, Y., Stoopler, M. B., Shen, Y., Cheng, H., Chen, J., MANSUKHANI, M. M., Koul, S., Halmos, B., & Borczuk, A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.0674 · Cited by 350 · see citing works

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

Ready, N., Farago, A. F., de Braud, F., Atmaca, A., Hellmann, M. D., Schneider, J. G., Spigel, D. R., Moreno, V., Chau, I., Hann, C. L., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.003 · Cited by 344 · see citing works

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With <i>EGFR</i> -Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer

Wu, Y.-L., Zhang, L., Kim, D.-W., Liu, X., Lee, D. H., Yang, J. C.-H., Ahn, M.-J., Vansteenkiste, J. F., Su, W.-C., Felip, E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.7326 · Cited by 333 · see citing works

A novel germ line juxtamembrane Met mutation in human gastric cancer

Lee, J., Han, S.-U., Cho, H., Jennings, B. A., Gerrard, B., Dean, M. C., Schmidt, L. S., Zbar, B., & Woude, G. F. V. (2000) · Oncogene · doi:10.1038/sj.onc.1203874 · Cited by 330 · see citing works

Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis

Xing, F., Liu, Y., Wu, S.-Y., Wu, K., Sharma, S., Mo, Y., Feng, J., Sanders, S., Jin, G., Singh, R. N., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1102 · Cited by 324 · see citing works

HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors

Shojaei, F., Lee, J. H., Simmons, B. H., Wong, A., Esparza, C. O., Plumlee, P. A., Feng, J., Stewart, A., Hu‐Lowe, D. D., & Christensen, J. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0489 · Cited by 321 · see citing works

Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma

Goyal, L., Muzumdar, M. D., & Zhu, A. X. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2791 · Cited by 307 · see citing works

The human met oncogene is related to the tyrosine kinase oncogenes

Dean, M. C., Park, M., Beau, M. M. L., et al. (1985) · Nature · doi:10.1038/318385a0 · Cited by 301 · see citing works

Expression and mutational analysis of MET in human solid cancers

Ma, P. C., Tretiakova, M., Mackinnon, A. C., Ramnath, N., Johnson, C. S., Dietrich, S., Seiwert, T. Y., Christensen, J. G., Jagadeeswaran, R., Krausz, T. N., et al. (2008) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20604 · Cited by 300 · see citing works

c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype

Li, Y.-Q., Li, A., Glas, M., Lal, B., Ying, M., Sang, Y., Xia, S., Trageser, D., Guerrero‐Cazares, H., Eberhart, C. G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016912108 · Cited by 266 · see citing works

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

Wu, Y.-L. L. C., Cheng, Y., Zhou, J., Lü, S., Zhang, Y., Zhao, J., Kim, D., Soo, R. A., Kim, S., Pan, H., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30154-5 · Cited by 257 · see citing works

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1

Smith, M. R., Bono, J. S. D., Sternberg, C. N., Moulec, S. L., Oudard, S. M., Giorgi, U. D., Krainer, M., Bergman, A. M., Hoelzer, W., de Wit, R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5597 · Cited by 248 · see citing works

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma

Schlumberger, M. J., Elisei, R., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L. F., Krajewska, J., Kreissl, M. C., Niederle, B., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx479 · Cited by 242 · see citing works

Recurrent MET fusion genes represent a drug target in pediatric glioblastoma

Bender, S., Gröbner, S. N., Pfaff, E., Kool, M., Northcott, P. A., Sturm, D., Worst, B. C., Pfister, S. M., Jones, D. T. W., van Tilburg, C. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4204 · Cited by 233 · see citing works

The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance

Huang, X., Gan, G., Wang, X., Xu, T., & Xie, W. (2019) · Autophagy · doi:10.1080/15548627.2019.1580105 · Cited by 228 · see citing works

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC

Recondo, G., Bahcall, M., Spurr, L. F., Che, J., Ricciuti, B., Leonardi, G. C., Lo, Y., Li, Y. Y., Lamberti, G., Nguyen, T. T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3608 · Cited by 226 · see citing works

Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.

Maulik, G., Kijima, T., Ma, P. C., et al. (2002) · PubMed · Cited by 225 · see citing works

Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma

Daniel, S. K., Sullivan, K. M., Labadie, K. P., & Pillarisetty, V. G. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0226-9 · Cited by 207 · see citing works

Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans

Che, L., Chi, W., Qiao, Y., Zhang, J., Song, X., Liu, Y., Li, L., Jia, J., Pilo, M. G., Wang, J., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317581 · Cited by 203 · see citing works

Functional Analysis of c-Met/Hepatocyte Growth Factor Pathway in Malignant Pleural Mesothelioma

Jagadeeswaran, R., Ma, P. C., Seiwert, T. Y., Jagadeeswaran, S., Zumba, O., Nallasura, V., Ahmed, S., Filiberti, R., Paganuzzi, M., Puntoni, R., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-04-4567 · Cited by 198 · see citing works

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial

Moro‐Sibilot, D., Cozic, N., Pérol, M., Mazières, J., Otto, J., Souquet, P. J., Bahleda, R., Wislez, M., Zalcman, G., de Guibert, S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz407 · Cited by 197 · see citing works

Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy.

Jankowski, K., Kucia, M., Wysoczynski, M., Reca, R., Zhao, D., Trzyna, E., Trent, J. O., Peiper, S. C., Zembala, M., Ratajczak, J., et al. (2003) · PubMed · Cited by 195 · see citing works

Identity of a tumor cytotoxic factor from human fibroblasts and hepatocyte growth factor

Higashio, K., Shima, N., Goto, M., et al. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)91287-3 · Cited by 194 · see citing works

The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions.

Soman, N. R., Corréa, P., Ruiz, B. A., et al. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.11.4892 · Cited by 190 · see citing works

Interplay between scatter factor receptors and B plexins controls invasive growth

Conrotto, P., Corso, S., Gamberini, S., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207650 · Cited by 188 · see citing works

Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer

Krishnaswamy, S., Kanteti, R., Duke‐Cohan, J. S., Loganathan, S., Liu, W., Ma, P. C., Sattler, M., Singleton, P. A., Ramnath, N., Innocenti, F., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0070 · Cited by 184 · see citing works

MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1

Li, H., Li, C., Li, X., Ding, Q., Guo, L., Liu, S., Liu, C., Lai, C., Hsu, J.-M., Dong, Q., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.252 · Cited by 184 · see citing works

Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer

Wu, Y.-L. L. C., Lü, S., Lü, Y., Zhou, J., Shi, Y., Sriuranpong, V., Ho, J., Ong, C. K., Tsai, C., Chung, C., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.06.012 · Cited by 179 · see citing works

c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma

Gibney, G. T., Aziz, S. A., Camp, R. L., Conrad, P. J., Schwartz, B. E., Chen, C. R., Kelly, W. K., & Kluger, H. M. (2012) · Annals of Oncology · doi:10.1093/annonc/mds463 · Cited by 177 · see citing works

Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma

Nault, J., Martin, Y., Caruso, S., Hirsch, T., Bayard, Q., Calderaro, J., Charpy, C., Copie-Bergman, C., Ziol, M., Bioulac-Sage, P., et al. (2020) · Hepatology · doi:10.1002/hep.30811 · Cited by 176 · see citing works

c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer

Lux, A., Kahlert, C., Grützmann, R., & Pilarsky, C. P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133305 · Cited by 168 · see citing works

MET in glioma: signaling pathways and targeted therapies

Cheng, F., & Guo, D. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1269-x · Cited by 164 · see citing works

The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma

Wang, H., Rao, B., Lou, J., Li, J., Liu, Z., Li, A., Cui, G., Ren, Z., & Yu, Z. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00055 · Cited by 164 · see citing works

Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation

Baltschukat, S., Engstler, B. S., Huang, A., Hao, H.-X., Tam, A., Wang, H. Q., Liang, J., DiMare, M. T., Bhang, H.-E. C., Wang, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2814 · Cited by 163 · see citing works

Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase.

Gandino, L., Longati, P., Médico, E., Prat, M., & Comoglio, P. M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42099-0 · Cited by 160 · see citing works

MET Signaling Regulates Glioblastoma Stem Cells

Joo, K. M., Jin, J., Kim, E. H., Kim, K. H., Kim, Y., Kang, B. G., Kang, Y.-J., Lathia, J. D., Cheong, K. H., Song, P. H., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3760 · Cited by 159 · see citing works

Validation of Met as a Therapeutic Target in Alveolar and Embryonal Rhabdomyosarcoma

Taulli, R., Scuoppo, C., Bersani, F., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4292 · Cited by 155 · see citing works

c-Met Is a Potentially New Therapeutic Target for Treatment of Human Melanoma

Puri, N., Ahmed, S., Janamanchi, V., Tretiakova, M., Zumba, O., Krausz, T. N., Jagadeeswaran, R., & Salgia, R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0776 · Cited by 155 · see citing works

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models

Engstrom, L. D., Aranda, R., Lee, M., Tovar, E. A., Essenburg, C. J., Madaj, Z., Chiang, H., Briere, D. M., Hallin, J. F., Lopez-Casas, P. P., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1192 · Cited by 149 · see citing works

Purification and initial characterization of a protein which facilitates assembly of nucleosome‐like structure from mammalian cells

Ishimi, Y., Hirosumi, J., Sato, W., et al. (1984) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1984.tb08305.x · Cited by 137 · see citing works

AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy

Bertrán-Alamillo, J., Cattan, V., Schoumacher, M., Codony‐Servat, J., Giménez-Capitán, A. A., Cantero, F., Burbridge, M. F., Rodríguez, S., Teixidó, C., Roman, R. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09734-5 · Cited by 137 · see citing works

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study

Kelley, R. K., Verslype, C., Cohn, A. L., Yang, T.-S., Su, W., Burris, H. A., Braiteh, F., Vogelzang, N. J., Spira, A. I., Foster, P., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw651 · Cited by 136 · see citing works

Safety and Tolerability of c-MET Inhibitors in Cancer

Puccini, A., Marín‐Ramos, N. I., Bergamo, F., Schirripa, M., Lonardi, S., Lenz, H., Loupakis, F., & Battaglin, F. (2019) · Drug Safety · doi:10.1007/s40264-018-0780-x · Cited by 133 · see citing works

Alveolar rhabdomyosarcoma: Is the cell of origin a mesenchymal stem cell?

Charytonowicz, E., Cordon‐Cardo, C., Matushansky, I., & Ziman, M. R. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.09.039 · Cited by 132 · see citing works

Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – A systematic review and meta-analysis

Vuong, H. G., Ho, A. T. N., Altibi, A. M. A., Nakazawa, T., Katoh, R., & Kondo, T. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.006 · Cited by 131 · see citing works

Des-γ-carboxy Prothrombin Is a Potential Autologous Growth Factor for Hepatocellular Carcinoma

Suzuki, M., Shiraha, H., Fujikawa, T., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406714200 · Cited by 126 · see citing works

Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma

Xie, Q. R., Bradley, R., Kang, L., Koeman, J. M., Ascierto, M. L., Worschech, A., Giorgi, V. D., Wang, E., Kefene, L., Su, Y., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119059109 · Cited by 126 · see citing works

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Bean, J. M., Brennan, C. W., Shih, J.-Y., Riely, G. J., Viale, A. J., Wang, L., Chitale, D. A., Motoi, N., Szőke, J., Broderick, S., et al. (2007) · Molecular Cancer Therapeutics · Cited by 123 · see citing works

Identification of the Receptor Tyrosine Kinase c-Met and Its Ligand, Hepatocyte Growth Factor, as Therapeutic Targets in Clear Cell Sarcoma

Davis, I. J., McFadden, A. W., Zhang, Y., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1121 · Cited by 118 · see citing works

Noncoding Mutations of HGF Are Associated with Nonsyndromic Hearing Loss, DFNB39

Schultz, J. M., Khan, S. N., Ahmed, Z. M., et al. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2009.06.003 · Cited by 116 · see citing works

Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase.

Rodrigues, G. A., & Park, M. (1994) · PubMed · Cited by 114 · see citing works

Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC).

Drilon, A. E. D. C., Camidge, D. R., Ou, S. I., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.108 · Cited by 114 · see citing works

Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization

Tong, C. Y., Hui, A. B.-Y., Yin, X.-L., et al. (2004) · Journal of Neurosurgery Pediatrics · doi:10.3171/ped.2004.100.2.0187 · Cited by 111 · see citing works

MET: roles in epithelial-mesenchymal transition and cancer stemness

Jeon, H.-M., & Lee, J. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2016.12.67 · Cited by 101 · see citing works

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’

Schöffski, P., Woźniak, A., Stacchiotti, S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx527 · Cited by 101 · see citing works

High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer

Zagouri, F., Bagó-Horváth, Z., Rössler, F., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.31 · Cited by 100 · see citing works

c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival

Lee, S. J., Lee, J., Park, S. H., Park, J. O., Lim, H. Y., Kang, W. K., Park, Y. S., & Kim, S. T. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.02.013 · Cited by 98 · see citing works

Paracrine HGF/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP/HIF-1α

Yan, B., Jiang, Z., Cheng, L., Chen, K., Zhou, C., Sun, L., Qian, W., Li, J., Cao, J., Xu, Q., et al. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.07.041 · Cited by 96 · see citing works

S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab

Burbridge, M. F., Bossard, C. J., Saunier, C., Fejes, I., Bruno, A., Léonce, S., Ferry, G., Violante, G. D., Bouzom, F., Cattan, V., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0075 · Cited by 93 · see citing works

Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma

Kondo, S., Ojima, H., Tsuda, H., Hashimoto, J., Morizane, C., Ikeda, M., Ueno, H., Tamura, K., Shimada, K., Kanai, Y., et al. (2012) · International Journal of Clinical Oncology · doi:10.1007/s10147-011-0361-9 · Cited by 92 · see citing works

Cell-Autonomous and Non–Cell-Autonomous Mechanisms of HGF/MET–Driven Resistance to Targeted Therapies: From Basic Research to a Clinical Perspective

Corso, S., & Giordano, S. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0040 · Cited by 92 · see citing works

Frequent silencing of a putative tumor suppressor gene melatonin receptor 1 A (MTNR1A) in oral squamous‐cell carcinoma

Nakamura, E., Kozaki, K., Tsuda, H., Suzuki, E., Pimkhaokham, A., Yamamoto, G., Irié, T., Tachikawa, T., Amagasa, T., Inazawa, J., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00838.x · Cited by 91 · see citing works

Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Li, A., Yang, J., Zhang, X., Zhang, Z., Su, J., Gou, L.-Y., Bai, Y., Zhou, Q. H., Yang, Z., Han‐Zhang, H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3273 · Cited by 91 · see citing works

Hepatocyte Growth Factor/Scatter Factor (HGF/SF) Induces Vascular Permeability Factor (VPF/VEGF) Expression by Cultured Keratinocytes

Gille, J., Khalik, M., König, V., & Kaufmann, R. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00418.x · Cited by 89 · see citing works

Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and β-catenin/Wnt pathways

Previdi, S., Maroni, P., Matteucci, E., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.036 · Cited by 89 · see citing works

Alterations and hypermethylation of thep14ARF gene in gastric cancer

Iida, S., Akiyama, Y., Nakajima, T., Ichikawa, W., Nihei, Z., Sugihara, K., & Yuasa, Y. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000901)87:5 · Cited by 88 · see citing works

Hepatopoietin A: partial characterization and trypsin activation of a hepatocyte growth factor.

Thaler, F., & Michalopoulos, G. K. (1985) · PubMed · Cited by 86 · see citing works

Cross-activating c-Met/β1 integrin complex drives metastasis and invasive resistance in cancer

Jahangiri, A., Nguyen, A. T., Chandra, A., Sidorov, M. K., Yagnik, G., Rick, J. W., Han, S. W., Chen, W. C., Flanigan, P. M., Schneidman‐Duhovny, D., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1701821114 · Cited by 86 · see citing works

Prognostic value of c-Met in colorectal cancer: A meta-analysis

Liu, Y. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i12.3706 · Cited by 84 · see citing works

Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases

Yan, S., Jiao, X., Zou, H., & Li, K. (2015) · Diagnostic Pathology · doi:10.1186/s13000-015-0296-y · Cited by 80 · see citing works

Increased expression of Met protein is associated with up‐regulation of hypoxia inducible factor‐1 (HIF‐1) in tumour cells in papillary carcinoma of the thyroid

Scarpino, S., d’Alena, F. C., Napoli, A. D., Pasquini, A., Marzullo, A., & Ruco, L. (2004) · The Journal of Pathology · doi:10.1002/path.1522 · Cited by 79 · see citing works

Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion

Asaoka, Y., Tada, M., Ikenoue, T., Seto, M., Imai, M., Miyabayashi, K., Yamamoto, K., Yamamoto, S., Kudo, Y., Mohri, D., et al. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.03.120 · Cited by 78 · see citing works

Hepatocyte growth factor/scatter factor (HGF/SF), the c-met receptor and the behaviour of epithelial cells.

Gherardi, E., Sharpe, M., Lane, K., et al. (1993) · PubMed · Cited by 69 · see citing works

The Met/Hepatocyte growth factor receptor (HGFR) gene is overexpressed in some cases of human leukemia and lymphoma

Jücker, M., Günther, A., Gradl, G., et al. (1994) · Leukemia Research · doi:10.1016/0145-2126(94)90003-5 · Cited by 67 · see citing works

Germline and Somatic Mutations in the Tyrosine Kinase Domain of the MET Proto-Oncogene in Papillary Renal Carcinomas

Schmidt, L. S., Duh, F. M., Chen, F., et al. (1998) · The Journal of Urology · doi:10.1016/s0022-5347(01)63909-0 · Cited by 65 · see citing works

IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway

Huang, W.-C., Tung, S.-L., Chen, Y., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4529-9 · Cited by 65 · see citing works

Clinical Significance of c-met Oncogene Alterations in Human Colorectal Cancer

Umeki, K., Shiota, G., & Kawasaki, H. (1999) · Oncology · doi:10.1159/000011985 · Cited by 64 · see citing works

A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma.

Lee, S. J., Lee, J., Sohn, I., et al. (2013) · PubMed · Cited by 63 · see citing works

Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx

Aebersold, D. M., Landt, O., Berthou, S., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206968 · Cited by 63 · see citing works

Targeting HGF/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma

Dai, L., Trillo-Tinoco, J., Cao, Y., et al. (2015) · Blood · doi:10.1182/blood-2015-07-658823 · Cited by 63 · see citing works

The prospect of precision therapy for renal cell carcinoma

Ciccarese, C., Brunelli, M., Montironi, R., Fiorentino, M., Iacovelli, R., Heng, D. Y. C., Tortora, G., & Massari, F. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.07.003 · Cited by 63 · see citing works

A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population

Gow, C., Hsieh, M., Wu, S., & Shih, J. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.12.001 · Cited by 62 · see citing works

Met is involved in TIGAR-regulated metastasis of non-small-cell lung cancer

Shen, M., Zhao, X., Zhao, L., Shi, L., An, S., Huang, G., & Liu, J. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0839-4 · Cited by 53 · see citing works

MET Inhibition Elicits PGC1α-Dependent Metabolic Reprogramming in Glioblastoma

Zhang, Y., Nguyen, T. T. T., Shang, E., Mela, A., Humala, N., Mahajan, A., Zhao, J., Shu, C., Torrini, C., Sanchez‐Quintero, M. J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1389 · Cited by 52 · see citing works

Predictive Value of Plasma Hepatocyte Growth Factor/Scatter Factor Levels in Patients with Clinically Localized Prostate Cancer

Gupta, A., Karakiewicz, P. I., Roehrborn, C. G., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5110 · Cited by 51 · see citing works

Road to stemness in hepatocellular carcinoma

Flores-Téllez, T. D. N. J., Villa‐Treviño, S., & Piña‐Vázquez, C. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i37.6750 · Cited by 51 · see citing works

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma

van den Bent, M. J., Azaro, A., Vos, F. D., Sepúlveda-Sánchez, J. M., Yung, W. K. A., Wen, P. Y., Lassman, A. B., Joerger, M., Tabatabai, G., Rodon, J. A., et al. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03337-2 · Cited by 51 · see citing works

SOX13 promotes colorectal cancer metastasis by transactivating SNAI2 and c-MET

Du, F., Li, X., Feng, W., Qiao, C., Chen, J., Jiang, M., Qiu, Z., Qian, M., Tian, D., Nie, Y., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1233-4 · Cited by 51 · see citing works

Constitutive activation of c‐Met is correlated with c‐Met overexpression and dependent on cell–matrix adhesion in lung adenocarcinoma cell lines

Nakamura, Y., Matsubara, D., Goto, A., et al. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00640.x · Cited by 50 · see citing works

Cancer-associated fibroblasts enhance the chemoresistance of CD73+ hepatocellular carcinoma cancer cells via HGF-Met-ERK1/2 pathway

Peng, H., Xue, R., Ju, Z., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-1038 · Cited by 50 · see citing works

In Vivo c-Met Pathway Inhibition Depletes Human Glioma Xenografts of Tumor-Propagating Stem-Like Cells

Rath, P., Lal, B., Ajala, O., Li, Y.-Q., Xia, S., Kim, J., & Laterra, J. (2013) · Translational Oncology · doi:10.1593/tlo.13127 · Cited by 49 · see citing works

HGF-independent regulation of MET and GAB1 by nonreceptor tyrosine kinase FER potentiates metastasis in ovarian cancerPreprint

Fan, G., Zhang, S., Gao, Y., et al. (2016) · Genes & Development · doi:10.1101/gad.284166.116 · Cited by 49 · see citing works

Clinicopathological significance and concordance analysis of c-MET immunohistochemistry in non-small cell lung cancers: A meta-analysis

Pyo, J., Kang, G., Cho, W. J., et al. (2016) · Pathology - Research and Practice · doi:10.1016/j.prp.2016.05.006 · Cited by 48 · see citing works

Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein

Navis, A. C., van Lith, S. A. M., van Duijnhoven, S. M. J., de Pooter, M., Yetkin-Arik, B., Wesseling, P., Hendriks, W. J. A. J., Venselaar, H., Timmer, M., van Cleef, P., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1420-5 · Cited by 46 · see citing works

MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma

Catenacci, D. V. T., Ang, A. L., Liao, W., Shen, J., O’Day, E., Loberg, R. D., Cecchi, F., Hembrough, T., Ruzzo, A., & Graziano, F. (2016) · Cancer · doi:10.1002/cncr.30437 · Cited by 46 · see citing works

Targeted therapy for metastatic renal cell carcinoma

Hofmann, F., Marconi, L. S., Stewart, F. J., Lam, T. B. L., Bex, A., Canfield, S. E., & Ljungberg, B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012796 · Cited by 46 · see citing works

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial

Saltarella, I., Morabito, F., Giuliani, N., Terragna, C., Omedè, P., Palumbo, A. P., Bringhen, S., Paoli, L. D., Martino, E. A., Larocca, A., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0691-4 · Cited by 46 · see citing works

Targeted therapy for metastatic renal cell carcinoma

Hofmann, F., Hwang, E. C., Lam, T. B. L., Bex, A., Yuan, Y., Marconi, L. S., & Ljungberg, B. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012796.pub2 · Cited by 45 · see citing works

A mutation of MET, encoding hepatocyte growth factor receptor, is associated with human DFNB97 hearing loss

Mujtaba, G., Schultz, J. M., Imtiaz, A., et al. (2015) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2015-103023 · Cited by 44 · see citing works

Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review

Kim, J. H., Kim, H. S., Kim, B. J., Jang, H. J., & Lee, J. (2017) · Oncotarget · doi:10.18632/oncotarget.20087 · Cited by 43 · see citing works

The clinical value of hepatocyte growth factor and its receptor—c-met for liver cancer patients with hepatectomy

Wu, F., WU, L., Zheng, S., Ding, W., Teng, L., Wang, Z., Ma, Z., & ZHAO, W. (2006) · Digestive and Liver Disease · doi:10.1016/j.dld.2006.03.007 · Cited by 42 · see citing works

HGF/c-Met Signalling in the Tumor Microenvironment

Zambelli, A., Biamonti, G., & Amato, A. M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-47189-7_2 · Cited by 41 · see citing works

Potentiation of invasive activity of hepatoma cells by reactive oxygen species is mediated by autocrine/paracrine loop of hepatocyte growth factor

Miura, Y., Kozuki, Y., & Yagasaki, K. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00725-3 · Cited by 39 · see citing works

Role of HGF/c‐Met in the treatment of colorectal cancer with liver metastasis

Yao, J., Li, X., Yan, L., He, S., Zheng, J., Wang, X., Zhou, P., Zhang, L., Wei, G., & Sun, X. (2019) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22316 · Cited by 39 · see citing works

The dual blockade of MET and VEGFR2 signaling demonstrates pronounced inhibition on tumor growth and metastasis of hepatocellular carcinoma

Zhang, Y., Gao, X., Zhu, Y., Kadel, D., Sun, H., Chen, J., Luo, Q., Sun, H., Yang, L., Yang, J., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0750-2 · Cited by 38 · see citing works

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer

Wakelee, H. A., Gettinger, S. N., Engelman, J. A., et al. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3283-z · Cited by 37 · see citing works

Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data

Szturz, P., Budı́ková, M., Vermorken, J. B., et al. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.09.009 · Cited by 37 · see citing works

α-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells

Michikoshi, H., Nakamura, T., Sakai, K., Suzuki, Y., Adachi, E., Matsugo, S., & Matsumoto, K. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.03.008 · Cited by 35 · see citing works

Prognostic value of c-Met overexpression in pancreatic adenocarcinoma: a meta-analysis

Kim, J. H., Kim, H. S., Kim, B. J., Lee, J., & Jang, H. J. (2017) · Oncotarget · doi:10.18632/oncotarget.20392 · Cited by 35 · see citing works

C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas

Marona, P., Górka, J., Kotlinowski, J., Majka, M., Jura, J., & Miękus, K. (2019) · Cells · doi:10.3390/cells8030272 · Cited by 35 · see citing works

c‐Met expression of thyroid tissue with special reference to papillary carcinoma

Oyama, T., Ichimura, E., Sano, T., et al. (1998) · Pathology International · doi:10.1111/j.1440-1827.1998.tb03835.x · Cited by 34 · see citing works

Prognostic value of MET copy number gain in non-small-cell lung cancer: an updated meta-analysis

Kim, J. H., Kim, H. S., & Kim, B. J. (2018) · Journal of Cancer · doi:10.7150/jca.24980 · Cited by 34 · see citing works

Targeting slug-mediated non-canonical activation of c-Met to overcome chemo-resistance in metastatic ovarian cancer cells

Chang, L., Hu, Y. W., Fu, Y., Zhou, T., You, J., Du, J., Zheng, L., Cao, J., Ying, M., Dai, X., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.03.001 · Cited by 34 · see citing works

Diagnosis and Prognostic Significance of c-Met in Cervical Cancer: A Meta-Analysis

Peng, J., Qi, S., Wang, P., et al. (2016) · Disease Markers · doi:10.1155/2016/6594016 · Cited by 33 · see citing works

Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review

Kim, J. H., Kim, B. J., & Kim, H. S. (2017) · Oncotarget · doi:10.18632/oncotarget.20796 · Cited by 33 · see citing works

Noncoding Microdeletion in Mouse Hgf Disrupts Neural Crest Migration into the Stria Vascularis, Reduces the Endocochlear Potential, and Suggests the Neuropathology for Human Nonsyndromic Deafness DFNB39

Morell, R. J., Olszewski, R. T., Tona, R., Leitess, S., Wafa, T. T., Taukulis, I., Schultz, J. M., Thomason, E. J., Richards, K., Whitley, B. N., et al. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.2278-19.2020 · Cited by 33 · see citing works

A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk.

Choueiri, T. K., Albiges, L. K., Powles, T. B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.6_suppl.tps767 · Cited by 33 · see citing works

Prognostic Significance of Targetable Angiogenic and Growth Factors in Patients Undergoing Resection for Gastric and Gastroesophageal Junction Cancers

Park, D. J., Yoon, C., Thomas, N. J., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3429-0 · Cited by 31 · see citing works

Met/HGF receptor activation is regulated by juxtamembrane Ser985 phosphorylation in hepatocytes

Nakayama, M., Sakai, K., Yamashita, A., et al. (2013) · Cytokine · doi:10.1016/j.cyto.2013.04.006 · Cited by 31 · see citing works

First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours

Rodon, J. A., Postel-Vinay, S. C., Hollebecque, A., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.007 · Cited by 30 · see citing works

Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression

Skrzypek, K., Kusienicka, A., Szewczyk, B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5145 · Cited by 29 · see citing works

Predictive role of the overexpression for CXCR4, C-Met, and VEGF-C among breast cancer patients: A meta-analysis

Wang, F., Li, S., Zhao, Y., et al. (2016) · The Breast · doi:10.1016/j.breast.2016.04.016 · Cited by 29 · see citing works

Correlation between HGF/c-Met and Notch1 signaling pathways in human gastric cancer cells

Huang, K., Sung, I.-C., Fang, W., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6447 · Cited by 29 · see citing works

Prognostic role of c-Met in head and neck squamous cell cancer tissues: a meta-analysis

Všianský, V., Gumulec, J., Raudenská, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28672-8 · Cited by 28 · see citing works

Induction of tumor initiation is dependent on CD44s in c-Met+ hepatocellular carcinoma

Dang, H. T., Steinway, S. N., Ding, W., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1166-4 · Cited by 27 · see citing works

A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma

Kong, L. R., Salleh, N. A. B. M., Ong, R., Tan, T. Z., Syn, N. L. X., Goh, R. M., Fhu, C. W., Tan, D. S. W., Iyer, N. G., Kannan, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15318-5 · Cited by 26 · see citing works

The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program

Aparicio, T., Cozic, N., de la Fouchardière, C., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00811-8 · Cited by 26 · see citing works

A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers

Roohullah, A., Cooper, A. J., Lomax, A. J., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0588-7 · Cited by 24 · see citing works

HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors

Penuel, E. M., Li, C., Parab, V. Y., Burton, L., Cowan, K. J., Merchant, M. A., Yauch, R. L., Patel, P. H., Peterson, A., Hampton, G. M., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0015 · Cited by 22 · see citing works

Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma

Kubo, Y., Fukushima, S., Inamori, Y., Tsuruta, M., Egashira, S., Yamada‐Kanazawa, S., Nakahara, S., Tokuzumi, A., Miyashita, A., Aoi, J., et al. (2018) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2018.10.001 · Cited by 22 · see citing works

Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report

Wang, Y., Chen, Z., Han, X., et al. (2020) · The Oncologist · doi:10.1002/onco.13545 · Cited by 21 · see citing works

Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors

Doi, T., Matsubara, N., Kawai, A., Naka, N., Takahashi, S., Uemura, H., & Yamamoto, N. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00859-4 · Cited by 20 · see citing works

Expression of growth-regulated oncogene-1, hepatocyte growth factor, platelet-derived growth factor-AA and soluble E-selectin and their association with high-risk human papillomavirus infection in squamous cell carcinoma of the uterine cervix

Zhang, Y., WU, J.-Z., YANG, Y.-Q., et al. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2293 · Cited by 18 · see citing works

C-Met as a potential novel prognostic marker in squamous cell carcinoma and adenocarcinoma of esophagus: evidence from a meta-analysis

Ren, J. L., Wu, H., Wang, W., et al. (2017) · Panminerva Medica · doi:10.23736/s0031-0808.16.03228-6 · Cited by 17 · see citing works

Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation

Park, K., Chang, G., Curigliano, G., Lim, W., Soo, R. A., Molina‐Vila, M. Á., Cattan, V., Darville, H., Gandossi, E., Smutná, V., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.03.012 · Cited by 15 · see citing works

Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer

Tsuji, T., Sakamori, Y., Ozasa, H., Yagi, Y., Ajimizu, H., Yasuda, Y., Funazo, T. Y., Nomizo, T., Yoshida, H., Nagai, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17895 · Cited by 14 · see citing works

A phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor-risk.

Choueiri, T. K., Albiges, L. K., Powles, T. B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.tps5102 · Cited by 14 · see citing works

Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cM et as a negative prognostic factor

Schiefer, A., Mesteri, I., Berghoff, A. S., Haitel, A., Schmidinger, M., Preusser, M., & Birner, P. (2015) · Histopathology · doi:10.1111/his.12709 · Cited by 13 · see citing works

Disease-dependent reciprocal phosphorylation of serine and tyrosine residues of c-Met/HGF receptor contributes disease retardation of a transgenic mouse model of ALS

Kadoyama, K., Funakoshi, H., Ohya, W., Nakamura, T., Matsumoto, K., Matsuyama, S., & Nakamura, T. (2009) · Neuroscience Research · doi:10.1016/j.neures.2009.06.016 · Cited by 13 · see citing works

The clinical value of serum hepatocyte growth factor levels in patients undergoing primary radiotherapy for glioma: effect on progression-free survival

Liang, Q., Mo, Z.-Y., Wang, P., et al. (2014) · Medical Oncology · doi:10.1007/s12032-014-0122-5 · Cited by 12 · see citing works

Evaluation of Intratumoral and Intertumoral Heterogeneity of MET Protein Expression in Gastric Cancer

Choi, J., Lee, H. E., Lee, H. S., et al. (2017) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000448 · Cited by 12 · see citing works

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works

Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges

Ubanako, P., Mirza, S., Ruff, P., & Penny, C. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1447953 · Cited by 68 · see citing works

An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives

Ye, Q., Zhou, X., Ren, H., Han, F., Lin, R., & Li, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1274336 · Cited by 15 · see citing works

Reimagining cancer treatments in the era of generative AI

Derbal, Y. (2025) · DIGITAL HEALTH · doi:10.1177/20552076251394631 · Cited by 4 · see citing works

The Expression of c-MET (HGF Receptor) Represents Poor Prognosis of Patients with pT3 Colon Carcinoma

Kobayashi, K., Okuyama, T., Nakamura, T., et al. (2006) · 日本消化器外科学会雑誌 · doi:10.5833/jjgs.39.23

Hepatocyte growth factor and its receptor/c-MET regulate both cell growth and invasion of human pancreatic cancer(膵癌細胞の増殖及び浸潤能における肝細胞増殖因子(HGF)とそのレセプター(c-MET)の役割)

長谷川, 恭. (1997) · Medical Entomology and Zoology · doi:10.11501/3129715

Involvement of c-Met/Hepatocyte Growth Factor Pathway in Cholangiocarcinoma Cell Invasion and Its Therapeutic Inhibition With Small Interfering RNA Specific for c-Met

Leelawat, K., Leelawat, S., Tepaksorn, P., et al. (2006) · Journal of Surgical Research · doi:10.1016/j.jss.2006.05.031 · Cited by 46 · see citing works

Expression of hepatocyte growth factor receptor in flbroblasts induced by high glucose

Ni, Z. (2002) · Zhonghua shenzangbing zazhi

[Dysregulation of HGF/c-Met signal pathway and their targeting drugs in lung cancer].

Li, Y., Liu, H., & Chen, J. (2014) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2014.08.08 · Cited by 5 · see citing works